Endovascular Therapy Demonstrates Benefit over Intravenous Recombinant Tissue Plasminogen Activator Based on Repeatedly Measured National Institutes of Health Stroke Scale

Publisher： Karger

E-ISSN： 1664-5545|6|1-2|25-30

ISSN： 1664-9737

Source： Interventional Neurology, Vol.6, Iss.1-2, 2016-10, pp. : 25-30

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Early Neurological Deterioration following Intravenous Recombinant Tissue Plasminogen Activator Therapy in Patients with Acute Lacunar Stroke

By  

Cerebrovascular Diseases, Vol. 26, Iss. 4, 2008-08 ,pp. : 355-359

Karger

Access to resources Recommend Favorite

Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator in a Stroke Patient Treated with Dabigatran

By  

Cerebrovascular Diseases, Vol. 30, Iss. 5, 2010-09 ,pp. : 533-534

Karger

Access to resources Recommend Favorite

Negative Fluid-Attenuated Inversion Recovery- Based Intravenous Thrombolysis Using Recombinant Tissue Plasminogen Activator in Acute Stroke Patients with Unknown Onset Time

By  

Cerebrovascular Diseases Extra, Vol. 3, Iss. 1, 2013-03 ,pp. : 35-45

Karger

Access to resources Recommend Favorite

Intravenous Recombinant Tissue Plasminogen Activator Therapy for Stroke Patients Receiving Maintenance Hemodialysis: The Stroke Acute Management with Urgent Risk-Factor Assessment and Improvement (SAMURAI) rt-PA Registry

By  

European Neurology, Vol. 66, Iss. 1, 2011-06 ,pp. : 37-41

Karger

Access to resources Recommend Favorite

Repeated Intravenous Treatment with Recombinant Tissue-Type Plasminogen Activator in Patients with Acute Ischemic Stroke

By  

European Neurology, Vol. 74, Iss. 3-4, 2015-09 ,pp. : 127-134

Karger

Access to resources Recommend Favorite